Analysts downgraded their ratings and price targets for DocuSign Inc. on a softer revenue outlook for Q4 FY21 and FY22. JPMorgan analyst Sterling Auty downgraded to Underweight from Neutral with a $175 price target, implying a 25.2 percent downside to Thursday’s closing price of $233.82. Pandemic tailwinds “came to a much faster than expected halt” in Q3. DocuSign’s sales now need to pivot from a focus on demand fulfillment to demand generation, which will lead to revenue growth seeing a “noticeable deceleration” into the first half of the next fiscal year. Auty thinks the shares could underperform software peers during this timeframe even though DocuSign’s long-term market opportunity “remains robust.” UBS analyst Karl Keirstead downgraded to Neutral from Buy with a price target of $170, down from $350, implying a 27.3 percent downside. The company reported a “thesis-changing print” with billings growth of just 28 percent and guidance for just …